Abstract
The present contribution has originated from a critical biomedical engineering issue e.g., loosening of metallic prostheses fixed with poly(methyl methylacrylate) (PMMA) bone cement especially in the case of hip joint replacement which ultimately forces the patient to undergo a revision surgery. Subsequently surgeons invented a cementless fixation technology introducing a bioactive hydroxyapatite (HAp) coating to the metallic implant surface. A wide variety of different coating methods have been developed to make the HAp coating on metallic implants more reliable; of which ultimately the plasma spraying method has been commercially accepted. However, the story was not yet finished at all, as many questions were raised regarding coating adherence, stability and bio-functionality in both in vitro and in vivo environments. Moreover, it has been now realized that the conventional high power plasma spraying (i.e. conventional atmospheric plasma spraying, CAPS) coating method creates many disadvantages in terms of phase impurity; reduced porosity limiting osseointegration and residual stresses which ultimately lead to inadequate mechanical properties and delamination of the coating. Further, poor crystallinity of HAp deposited by CAPS accelerates the rate of bioresorption, which may cause poor adhesion due to quick mass loss of HAp coatings. Therefore, in the present work a very recently developed method e.g. low power microplasma spraying method was utilized to coat HAp on SS316L substrates to minimize the aforementioned problems associated with commercial CAPS HAp coatings. Surgical grade SS316L has been chosen as the substrate material because it is more cost effective than Ti6Al4V and CoCrMo alloys.